RFS/DFS

mML - NA - all population metastatic/adv melanoma (mML) mML - (neo)adjuvant (NA) mML - NA - all population

versus nivolumab alone
nivolumab plus ipilimumab vs. nivolumab alone 1 1.0better0.35.0100 %
versus placebo
nivolumab plus ipilimumab vs. placebo 1 1.0better0.35.0100 %